Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMTKC6)

Drug Name

TEV-48125 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Migraine	8A80	Phase 3	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Calcitonin gene-related peptide (CALC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Eptinezumab	DM5LJCI	Migraine	8A80	Approved	[3]
ALD-403	DM6RBYT	Migraine	8A80	Phase 2	[4]
PF-4427429	DM3427C	Migraine	8A80	Phase 1	[5]
CGRP	DMCRPKS	Asthma	CA23	Discontinued in Phase 2	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Calcitonin gene-related peptide (CALC)	TTAFORY	NOUNIPROTAC	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03303105) Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine. U.S. National Institutes of Health.
2	TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points. Neurology. 2016 Jul 5;87(1):41-8.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
4	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
5	Teva Announces Positive Results for TEV-48125 in Phase IIb Chronic Migraine Study Meeting Primary and Secondary Endpoints
6	Calcitonin gene-related peptide as inflammatory mediator.Pulm Pharmacol Ther.2003;16(3):121-30.